Global Bone And Joint Health Supplements Market Trends and Insights
Rising global incidence of osteoporosis and joint-related disorders
The rising prevalence underscores a critical and growing demand for effective osteoporosis-related healthcare solutions, which now transcend traditional demographic boundaries. In 2023, the Italian National Institute of Statistics reported that 4.47 million individuals in Italy were affected by osteoporosis. The data highlights that the economic burden of untreated bone loss significantly exceeds the costs associated with routine supplementation and preventive care. As a result, healthcare professionals are increasingly advocating for the early adoption of targeted nutritional and therapeutic products. This proactive approach is broadening the addressable consumer base, encompassing not only the elderly population, who are traditionally at higher risk but also younger individuals who can benefit from preventive interventions aimed at mitigating long-term health risks.Aging population with increased focus on mobility and bone strength
Demographic shifts are transforming demand patterns, extending beyond basic metrics of population aging. As of January 2024, the European Union reported a population of 449.3 million, with over one-fifth (21.6%) aged 65 and older. This demographic trend has led to an increase in disability-adjusted life years, particularly linked to musculoskeletal conditions. Rising life expectancy has heightened the demand for prolonged joint functionality. Consequently, there is growing interest in daily essentials such as collagen peptides, glucosamine, and vitamin K2, which are now viewed as integral to daily health rather than occasional remedies. The combination of an aging population and the increasing prevalence of related disorders is driving market demand, surpassing simple demographic projections. Older adults are becoming more proactive in maintaining mobility and independence. A notable trend of “healthy aging” has emerged, where older consumers prioritize preventive measures by investing in supplements rather than waiting for symptoms to manifest.Regulatory challenges for health claims restrict growth
Structure/function claims are exempt from pre-market approval; however, every product label must include a disclaimer stating that the claim has not been reviewed by the FDA. This requirement can diminish consumer confidence in the product. Furthermore, the proposed removal of self-affirmed GRAS (Generally Recognized as Safe) status would necessitate companies to formally notify regulatory authorities about the inclusion of novel food ingredients. This change would result in extended product launch timelines and increased documentation-related expenses. Smaller companies, in particular, face significant challenges in complying with the differing regulatory frameworks of the United States, European Union, and China. These complexities disproportionately burden smaller firms and hinder innovation within the category.Other drivers and restraints analyzed in the detailed report include:
- Growing awareness of preventive healthcare and bone density management
- Shift toward natural and plant-based bone health ingredients
- High price of quality formulations deterring budget-conscious consumers
Segment Analysis
In 2025, vitamins and minerals accounted for 31.05% of total revenue, driven by strong endorsements from physicians for calcium-vitamin D regimens. Heightened awareness of vitamin D deficiency and its repercussions on bone health has spurred the demand for vitamin D supplements. Meanwhile, glucosamine-chondroitin is set to witness an 8.35% CAGR growth rate through 2031, fueled by findings that combination formulas with curcumin significantly alleviate pain more than glucosamine-chondroitin alone.As a result, the glucosamine-chondroitin segment within the bone and joint health supplements market is expanding at a faster pace than any other ingredient category. This rapid growth has attracted notable investments, such as Zeria USA’s introduction of pharmaceutical-grade sodium chondroitin. Additionally, collagen, which was traditionally marketed for its beauty-enhancing properties, is now transitioning towards being positioned as a functional ingredient for joint health, with marine-sourced variants gaining particular traction in this evolving market segment.
Complete Report Scope:
- By Product Type
- Vitamins and Minerals
- Collagen
- Glucosamine-Chondroitin
- Omega-3 Fatty Acids
- Other Product Types
- By Form
- Tablets
- Capsules/Softgels
- Gummies and Chews
- Powders
- Other Forms
- By Distribution Channel
- Supermarkets/Hypermarkets
- Specialty and Health Stores
- Online Retailers
- Other Distribution Channels
- By Geography
- North America
- United States
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- United Kingdom
- Italy
- France
- Netherlands
- Poland
- Belgium
- Sweden
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Australia
- Indonesia
- South Korea
- Thailand
- Singapore
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Colombia
- Chile
- Peru
- Rest of South America
- Middle East and Africa
- South Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- Egypt
- Morocco
- Turkey
- Rest of Middle East and Africa
- North America
Geography Analysis
In 2025, North America contributed 31.82% of global revenue, driven by established physician recommendations for calcium and vitamin D supplementation and a robust reimbursement framework. The FDA's 2024 approval of YORVIPATH (palopegteriparatide) highlights the seamless progression from supplements to advanced biologics, emphasizing the role of regulatory clarity in fostering innovation. E-commerce continues to grow steadily as consumers increasingly incorporate supplements into routine household purchases.Asia-Pacific, anticipated to grow at an 7.91% CAGR, demonstrates significant untapped potential. China alone accounts for 145.86 million osteoporotic adults, as per WHO standards, while regulators are working on provisions to permit joint-health claims on health food labels. Haleon's decision to increase its stake in Tianjin TSKF Pharmaceutical to 88% reflects a long-term strategic commitment. Additionally, brand extensions such as Caltrate for expectant mothers in the Philippines illustrate a focus on micro-segmentation. Factors such as rapid urbanization, rising disposable incomes, and the expansion of mobile commerce are driving the adoption of bone and joint health supplements, positioning the region for sustained growth.
Europe maintains stable mid-single-digit growth, supported by innovations in plant-based products. Marine collagen and algal calcium are gaining popularity among sustainability-conscious consumers. Regulatory harmonization under EFSA facilitates multi-country product launches but imposes stringent evidence requirements, favoring well-funded companies. The Middle East, Africa, and South America remain in the early stages of market development. However, increasing rates of obesity and diabetes are raising awareness of joint health, signaling potential opportunities as distribution infrastructure continues to improve.
List of Companies Covered in this Report:
- Amway Corporation
- Swanson Health Products, Inc.
- Nestle S.A.
- Haleon plc
- 21st Century HealthCare, Inc.
- Bluebonnet Nutrition Corporation
- Reckitt Benckiser Group plc
- Herbalife Nutrition Ltd.
- Otsuka Holdings Co., Ltd.
- Nordic Naturals
- NOW Foods
- Harbin Pharmaceutical Group Co., Ltd.
- Nutramax Laboratories Inc.
- Dr. Willmar Schwabe GmbH & Co. KG
- Life Extension Foundation Buyers Club, Inc.
- Xtend-Life Group Ltd.
- Codeage LLC
- Xiamen Kingdomway Group Company
- Vytalogy Wellness, L.L.C.
- BioGaia AB
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amway Corporation
- Swanson Health Products, Inc.
- Nestle S.A.
- Haleon plc
- 21st Century HealthCare, Inc.
- Bluebonnet Nutrition Corporation
- Reckitt Benckiser Group plc
- Herbalife Nutrition Ltd.
- Otsuka Holdings Co., Ltd.
- Nordic Naturals
- NOW Foods
- Harbin Pharmaceutical Group Co., Ltd.
- Nutramax Laboratories Inc.
- Dr. Willmar Schwabe GmbH & Co. KG
- Life Extension Foundation Buyers Club, Inc.
- Xtend-Life Group Ltd.
- Codeage LLC
- Xiamen Kingdomway Group Company
- Vytalogy Wellness, L.L.C.
- BioGaia AB

